Innovation Pharmaceuticals (OTCMKTS:IPIX) Stock In Focus After Recent Development

October 5, 2022

If you are looking into stocks that had clocked notable gains on Tuesday then you could do well to take a look at the Innovation Pharmaceuticals (OTCMKTS:IPIX) stock which had ended up with gains of 5% yesterday. The company announced yesterday that a scientific article had been published with regards to the antifungal properties of its product Brilacidin. Trading Data On Tuesday, IPIX stock gained 4.71% to $0.0356 with more…

Read More >>

Innovation Pharmaceuticals (OTCMKTS:IPIX) Stock Rockets After The News: What Next?

August 13, 2021

Innovation Pharmaceuticals (OTCMKTS:IPIX) jumped 18% after offering additional information about the randomized, placebo-controlled, double blinds phase II clinical study status evaluating Brilacidin in moderate-to-severed COVID-19 treatment in hospitalized patients. The company is advancing Brilacidin for COVID-19 treatment under a fast track designation. Enrollment in the study ended in June 2021, with the last patient follow-up visit occurring on July 30, 2021. Notably, the subject database is still blinded, focusing on…

Read More >>

Innovation Pharmaceuticals (IPIX) Stock Continues to See Selling Pressure

August 11, 2021

The Innovation Pharmaceuticals (OTCMKTS:IPIX) stock ran into a bit of trouble on Tuesday as it suffered from a strong selloff and ended the day with losses of as much as 14.50%. In this regard, it should be noted that there was no news at all about the clinical stage biopharmaceutical firm on Tuesday and the selloff in the stock appears fairly random. However, investors still need to get an idea…

Read More >>

Innovation Pharmaceuticals (OTCMKTS: IPIX) Completes Enrolment in Phase 2 Brilacidin Study in Hospitalized COVID-19 Patients

July 23, 2021

Innovation Pharmaceuticals (OTCMKTS: IPIX) has announced that it has met complete patient registration for its double-blind, randomized placebo-controlled second phase clinical study of Brilacidin in treating hospitalized patients with moderate to severe COVID-19. The company is developing the drug for COVID-19 treatment under the FDA Fast Track Designation. Innovation Pharmaceuticals enrolled 120 patients in the Brilacidin study  A total of 120 dosed participants were recruited across several sites for the…

Read More >>